Clinical Trial Update: A Study of GC101 TIL in Advanced Melanoma (BZ) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of GC101 TIL in advanced melanoma has completed, evaluating tumor-infiltrating lymphocyte therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GC101 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Tumor Infiltrating Lymphocytes, Safety | Phase 1, Phase 2 | Status: COMPLETED